Jecko Thachil: Interrupting Antiplatelet Therapy for Urgent and Planned Surgery
Jecko Thachil, MAHSC Professor, at the University of Manchester, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“Cardiovascular and cerebrovascular diseases are major causes of morbidity and morality in the world. Antiplatetelet therapies play a major role in the management of these conditions.
But when a patient receiving antiplatelet medications requires urgent or planned surgery, how do we deal with interrupting these treatments? Discussed in the following review.”
Title: How to undertake procedures while on antiplatelet agents: a hematologist’s view
Authors: Dawn Swan, Robert Turner, James Douketis, Jecko Thachil
Read the Full Article on RPTH.
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 15, 2026, 09:10Shall I Bleed Less with Age? Just 2 Weeks Until the Webinar – EHC
-
Apr 15, 2026, 08:51Moustafa Abdou: Sutimlimab is Transforming Outcomes in Cold Agglutinin Disease
-
Apr 15, 2026, 04:52Ulrich Pecks: Personalized Approaches to VTE Prevention in Pregnant Women with Inherited Thrombophilia
-
Apr 15, 2026, 04:06Brenda Pleasant: Insights from the HFA Symposium on Hemophilia Care
-
Apr 15, 2026, 03:43Lexy Halloran: Addressing Diagnostic Inequities in Women with Chronic Conditions
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS